title: Reduction of myocardial infarct size in rat by IRFI-048, a selective analogue of vitamin E.
abstract: The effects of IRFI-048 (2,3-dihydro-5-methoxy-4,6,7-trimethyl-2-benzofuranyl acetic acid), a selective analogue of Vitamin E, on myocardial tissue injury were examined in anaesthetized rats subjected to 60-min occlusion of the left coronary artery followed by 60-min reperfusion. Infarct size (Evan's blue and tetrazolium stain), serum creatinphosphokinase (CPK), plasma malonaldehyde (MAL), cardiac myeloperoxidase (MPO) activity, and ST-segment of electrocardiogram (ECG) and survival rate were evaluated. Postischaemic reperfusion produced severe cardiac necrosis, caused neutrophil (PMNs) infiltration (evaluated by MPO activity) in the jeopardized tissue, increased serum CPK and plasma MAL, raised ST-segment of ECG, and decreased survival rate. IRFI-048, (200 and 400 mg/kg o.s.) given to the rats 6 h before occlusion, caused a reduction of necrotic area expressed as a percentage of either the area at risk or the total left ventricle, decreased MPO activity both in the area at risk (from 3.2 +/- 0.3 U x 10(-3)/g tissue to 1.1 +/- 0.4 U x 10(-3)/g tissue; p < .005) and in the necrotic area (from 5.7 +/- 0.9 U x 10(-3)/g tissue to 1.8 +/- 0.5 U x 10(-3)/g tissue; p < .001), attenuated the rise of ST-segment of ECG (from 0.51 +/- 0.14 mV in the vehicle group to 0.28 +/- 0.11 mV in the treated group; p < .005), reduced the increase of plasma MAL and serum CPK during reperfusion (from 42 +/- 5.3 nmol/ml to 15 +/- 3.1 nmol/ml and 139 +/- 13 IU/100 ml to 58 +/- 7.5 IU/100 ml, respectively; p < .001).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Institute of Pharmacology, School of Medicine, University of Messina, Italy.
authors.forename: G M
authors.initials: GM
authors.lastname: Campo
authors.forename: F
authors.initials: F
authors.lastname: Squadrito
authors.forename: M
authors.initials: M
authors.lastname: Ioculano
authors.forename: D
authors.initials: D
authors.lastname: Altavilla
authors.forename: G
authors.initials: G
authors.lastname: Calapai
authors.forename: B
authors.initials: B
authors.lastname: Zingarelli
authors.forename: R
authors.initials: R
authors.lastname: Scuri
authors.forename: A P
authors.initials: AP
authors.lastname: Caputi
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001572:Benzofurans / Q000494:pharmacology*; D003402:Creatine Kinase / Q000097:blood; D004562:Electrocardiography / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D009206:Myocardium / Q000201:enzymology / Q000473:pathology*; D009336:Necrosis; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
chemical_list: D000975:Antioxidants; D001572:Benzofurans; C087875:2,3-dihydro-5-methoxy-4,6,7-trimethyl-2-benzofuranyl acetic acid; D008315:Malondialdehyde; D009195:Peroxidase; D003402:Creatine Kinase